FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Fuller

Research Profile

Chemicals & Drugs

Living Beings

Physiology

Procedures

Cloning, Molecular

Concepts & Ideas

Molecular Sequence Data

Co-author Network

Publications

TOP 3
Tomas Cihlar; Adrian S Ray; Genevieve Laflamme; Jennifer E Vela; Leah Tong; Michael D Fuller; Anupma Roy; Gerald R Rhodes
Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
Adrian S Ray; Tomas Cihlar; Kelly L Robinson; Leah Tong; Jennifer E Vela; Michael D Fuller; Lani M Wieman; Eugene J Eisenberg; Gerald R Rhodes
Mechanism of active renal tubular efflux of tenofovir.
Michael D Miller; Nicolas A Margot; PD Lamy; Michael D Fuller; KE Anton; Andrew S Mulato; Julie M Cherrington
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Fuller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Tomas Cihlar; Adrian S Ray; Genevieve Laflamme; Jennifer E Vela; Leah Tong; Michael D Fuller; Anupma Roy; Gerald R Rhodes
Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.
Antiviral therapy 2007;12(2):267-72.
2006: Adrian S Ray; Tomas Cihlar; Kelly L Robinson; Leah Tong; Jennifer E Vela; Michael D Fuller; Lani M Wieman; Eugene J Eisenberg; Gerald R Rhodes
Mechanism of active renal tubular efflux of tenofovir.
Antimicrobial agents and chemotherapy 2006;50(10):3297-304.
2001: Michael D Miller; Nicolas A Margot; PD Lamy; Michael D Fuller; KE Anton; Andrew S Mulato; Julie M Cherrington
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Journal of acquired immune deficiency syndromes (1999) 2001;27(5):450-8.
1999: Tomas Cihlar; DC Lin; John B Pritchard; Michael D Fuller; Dirk B Mendel; Douglas H Sweet
The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.
Molecular pharmacology 1999;56(3):570-80.
1998: Julie M Cherrington; Michael D Fuller; PD Lamy; Richard C Miner; Jacob P Lalezari; S Nuessle; W Lawrence Drew
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
The Journal of infectious diseases 1998;178(6):1821-5.
1998: Tomas Cihlar; Michael D Fuller; Andrew S Mulato; Julie M Cherrington
A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Virology 1998;248(2):382-93.
1998: Michael D Miller; PD Lamy; Michael D Fuller; Andrew S Mulato; Nicolas A Margot; Tomas Cihlar; Julie M Cherrington
Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.
Molecular pharmacology 1998;54(2):291-7.
1998: Tomas Cihlar; Michael D Fuller; Julie M Cherrington
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Journal of virology 1998;72(7):5927-36.
1997: X Xiong; C Flores; Michael D Fuller; Dirk B Mendel; Andrew S Mulato; K Moon; M S Chen; Julie M Cherrington
In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir).
Antiviral research 1997;36(2):131-7.
1997: Tomas Cihlar; Michael D Fuller; Julie M Cherrington
Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system.
Protein expression and purification 1997;11(2):209-18.
1997: Irene L Smith; Julie M Cherrington; R E Jiles; Michael D Fuller; William R Freeman; Stephen A Spector
High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.
The Journal of infectious diseases 1997;176(1):69-77.
1996: Julie M Cherrington; Andrew S Mulato; Michael D Fuller; MS Chen
Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.
Antimicrobial agents and chemotherapy 1996;40(9):2212-6.
1996: Julie M Cherrington; Michael D Fuller; Andrew S Mulato; S J Allen; S C Kunder; M A Ussery; Z Lesnikowski; Ray F Schinazi; J P Sommadossi; MS Chen
Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases.
Antimicrobial agents and chemotherapy 1996;40(5):1270-3.